30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Bacterin

4Q13 tissue revenue: $8.3MM, +2%

2013 tissue revenue: $33.1MM, flat

  • Business model going forward: direct sales to orthopaedics and neurosurgery via hybrid model; exploring private label relationships
  • Increased productivity: 25 sales employees generated more revenue in 4Q13 than 65 employees in 4Q12
  • Added 12 new sales staff since year-end (recruited from Biomet, DePuy, Globus, Medtronic); expecting up to 45 sales staff by end of 2014
  • Launched OsteoSTX in 1Q14, surgeons discussing use in multilevel fusion
  • 2014-2015 launches include more demineralized bone matrix (DBM) product configurations
  • Claims 6.5% share of U.S. DBM market, behind Medtronic, DePuy, Integra